# Natasha B. Leighl

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/natasha-b-leighl/

## Facts

| Field | Value |
| --- | --- |
| Citations | 45,248 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 87 |
| i10-index | 379 |
| Last Known Institution | University Health Network |
| OpenAlex ID | https://openalex.org/A5012748795 |
| ORCID iD | https://orcid.org/0000-0002-3249-4602 |
| Works | 963 |

## Researcher papers

Showing 12 of 13.

- [Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-for-the-treatment-of-non-small-cell-lung-cancer/)
- [Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline](https://scholariq.org/papers/management-of-immune-related-adverse-events-in-patients-treated-with-immune/)
- [Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial](https://scholariq.org/papers/early-palliative-care-for-patients-with-advanced-cancer-a-cluster-randomised/)
- [Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update](https://scholariq.org/papers/recommendations-for-the-use-of-wbc-growth-factors-american-society-of-clinical/)
- [Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes](https://scholariq.org/papers/large-scale-association-analysis-identifies-new-lung-cancer-susceptibility-loci/)
- [Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer](https://scholariq.org/papers/liquid-biopsy-for-advanced-nsclc-a-consensus-statement-from-the-international/)
- [Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study](https://scholariq.org/papers/amivantamab-in-egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/)
- [Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial](https://scholariq.org/papers/brigatinib-in-patients-with-crizotinib-refractory-anaplastic-lymphoma-kinase/)
- [Perceptions of palliative care among patients with advanced cancer and their caregivers](https://scholariq.org/papers/perceptions-of-palliative-care-among-patients-with-advanced-cancer-and-their/)
- [Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153](https://scholariq.org/papers/continuous-versus-1-year-fixed-duration-nivolumab-in-previously-treated-advanced/)
- [First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial](https://scholariq.org/papers/first-line-erlotinib-followed-by-second-line-cisplatin-gemcitabine-chemotherapy/)
- [Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)](https://scholariq.org/papers/safety-efficacy-and-patient-reported-health-related-quality-of-life-and-symptom/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [University Health Network](https://scholariq.org/institutions/university-health-network/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.